Background and Purpose-Atrial fibrillation (AF) is prevalent and there is a clinical need for biomarkers to identify individuals at higher risk for AF. Fixed throughout a life course and assayable early in life, genetic biomarkers may meet this need. Here, we investigate whether multiple single nucleotide polymorphisms together as an AF genetic risk score (AF-GRS) can improve prediction of one's risk for AF. Methods-In 27 471 participants of the Malmö Diet and Cancer Study, a prospective, community-based cohort, we used Cox models that adjusted for established AF risk factors to assess the association of AF-GRS with incident AF and ischemic stroke. Median follow-up was 14.4 years for incident AF and 14.5 years for ischemic stroke. The AF-GRS comprised 12 single nucleotide polymorphisms that had been previously shown to be associated with AF at genome-wide significance. Results-During follow-up, 2160 participants experienced a first AF event and 1495 had a first ischemic stroke event.
S
troke is the second leading cause of mortality worldwide, split almost evenly between ischemic and nonischemic stroke. 1 Atrial fibrillation (AF) and the commonly ensuing cardioembolic complications are an important cause of ischemic stroke. In the United States, AF has been estimated to affect ≈3 million adults and this number has been projected to double by 2050. [2] [3] [4] Approximately 20% to 25% of individuals will be affected by AF in their lifetime. 5, 6 In addition to cardioembolic stroke, AF is also associated with heart failure and other thromboembolic complications 4, 7, 8 and results in substantial public health costs. 9 Identifying individuals at the highest risk for AF and then aggressively addressing modifiable risk factors in these individuals may be beneficial with respect to health outcomes and cost. Risk factors for AF include hypertension, smoking, obesity, diabetes mellitus, age, male sex, and heart disease (myocardial infarction, heart failure, and valvular heart disease). 10 The fraction of the risk for AF attributable to these factors is ≈50%, 11 with hypertension being the most prominent modifiable risk factor.
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AF. [13] [14] [15] [16] [17] The heritability of AF has motivated genome-wide association studies that have screened for common single nucleotide polymorphisms (SNPs) associated with AF. To date, genome-wide association studies have identified 12 common SNPs that are associated with AF at genome-wide significance levels. [18] [19] [20] [21] [22] [23] Here, we build on these observations to test 2 hypotheses: (1) an AF genetic risk score (AF-GRS) that combines 12 SNPs is associated with risk for AF beyond established risk factors and (2) the same AF-GRS is associated with ischemic stroke. We tested these hypotheses in a large, population-based prospective study of middle-aged men and women.
Methods

Study Participants
The Malmö Diet and Cancer (MDC) study is a community-based, prospective observational study of 30 447 participants drawn from ≈230 000 residents of Malmö, Sweden. Men aged 46 to 73 years and women aged 45 to 73 years were invited to participate and were enrolled between 1991 and 1996. 24 Details of the MDC design have been reported previously. 24, 25 In the current study, we excluded participants who did not provide DNA with sufficient quantity or quality for genotyping (n=2693), participants with prevalent AF (n=282), and 1 participant who was lost to follow-up.
The primary end points of the study were time to first occurrence of AF and time to first occurrence of ischemic stroke. For incident ischemic stroke analyses, we also excluded participants with prevalent ischemic stroke (n=226).
Participants completed a baseline examination that included a medical history review, physical examination, and a blood draw. Blood pressure was measured using a mercury-column sphygmomanometer after 10 minutes of rest in the supine position. Hypertension was defined as systolic blood pressure of ≥140 mm Hg, diastolic blood pressure of ≥90 mm Hg, or use of antihypertensive medication. Prevalent diabetes mellitus was defined as previously described 26 by participants' report of a physician diagnosis, self-reported use of diabetes mellitus medication, fasting whole blood glucose ≥6.1 mmol/L (which corresponds to fasting plasma glucose ≥7.0 mmol/L), 27 or having been registered in local or national diabetes mellitus registries. Body mass index (BMI) was defined as body weight in kilograms divided by the square of height measured in meters. Current cigarette use was defined as any self-reported use within the past year. Prevalence of AF and ischemic stroke was based on the assessment of participants' medical records at baseline examination. Prevalent coronary heart disease was defined as a diagnosis code of myocardial infarction on the basis of International Classification of DiseasesNinth Revision (ICD-9) and ICD-10 codes 410 and I21, respectively. The MDC study protocols were approved by the ethics committee at Lund University. All participants provided written informed consent.
Determination of AF and Ischemic Stroke Outcomes
Incident AF and incident stroke events were assessed by ICD-8, ICD-9, and ICD-10 codes from The Swedish Hospital Discharge Register and the Swedish Cause of Death Register, which are administered by the Swedish National Board of Health and Welfare. AF was defined as a diagnosis code of 427.92 (ICD-8), 427D (ICD-9), or I48 (ICD-10). This definition of AF was shown to have a 94% validation rate from ECG records. 28 Ischemic stroke was defined on the basis of codes 434 (ICD-9) and code I63 (ICD-10). All ischemic stroke events that occurred within the catchment area of Malmö hospitals (92% of all events) were validated within the stroke registry in Malmö, 29 in which original medical records were examined including computed tomography and other imaging modalities, where available. Participants with transient ischemic attack were not included as a stroke event.
Hemorrhagic strokes (ICD-9 430, 431, or 432) were excluded from the analysis of incident ischemic strokes. The last assessment of incident events for MDC participants was performed in 2009.
Genotyping
Genotypes of the MDC participants were determined using a multiplex method that combines polymerase chain reaction, allele-specific oligonucleotide ligation assays, and hybridization to oligonucleotides coupled to Luminex 100TM xMAP microspheres (Luminex, Austin, TX).
30
Modeling of GRS
The AF-GRS includes 12 SNPs (Table 1) . These are all the SNPs that have been reported to be associated with AF at a genome-wide significance level (P<5×10 -8 ), including 4 SNPs at PITX2 locus. [18] [19] [20] [21] [22] [23] The linkage disequilibrium between these SNPs is presented in Figure I and Table I in the online-only Data Supplement. The AF-GRS for each individual in the current study was calculated as follows. For each SNP the natural log transformed risk estimate for the minor allele was multiplied by the number of minor alleles carried by that individual; these 12 products were then summed. The risk estimate for the minor allele at each SNP was obtained from the largest published study or from a published meta-analysis.
Statistical Analysis
All statistical analyses were performed in R. 31 Participant characteristics at baseline were described by count and percent or by mean and SD (Table 2) . Deviation from Hardy-Weinberg equilibrium assumptions was evaluated by an exact test for biallelic markers. The association of each SNP with incident AF was assessed from Cox proportional hazards regression models that were adjusted for age, sex, BMI, systolic and diastolic blood pressure, use of antihypertensive medications, current smoking, prevalent diabetes mellitus, coronary events, and heart failure. The association of the AF-GRS with incident AF or incident ischemic stroke was also assessed using Cox proportional hazards models. The cumulative fraction of events was estimated as 1 minus the Kaplan-Meier estimate of survival free of first AF event. The differences of the cumulative fraction of events between subgroups were assessed by the log-rank test. C-statistics were calculated by the method of Gönen and Heller. 32 To obtain unbiased estimates of the c-statistics, the data were randomly split into equal sized training and test sets. The training set was used to estimate the Cox model coefficients and the c-statistic was determined in the test set. To provide a P value for the difference between the c-statistics of 2 models, we randomly permuted the AF-GRS of the participants 10 000× and calculated the difference between the c-statistics of the 2 models for each iteration. The P value was calculated as the proportion of iterations in which the difference in c-statistics was as or more extreme than the observed difference. Continuous net reclassification improvement (NRI) was calculated according to Pencina et al. 33 The c-statistics and continuous NRI are reported for 10-year risk for incident AF events and for 15-year risk for incident ischemic stroke events that occurred after or coincident with a diagnosis of AF and are therefore based on events occurring in the first 10 and 15 years of follow-up, respectively.
Results
Study Population
The baseline characteristics of the 27 471 MDC participants in this study are provided in Table 2 . Median time at risk for incident AF and ischemic stroke was 14.4 and 14.5 years, respectively. During follow-up, 2160 participants experienced a first AF event and 1495 participants experienced a first ischemic stroke event. Of those participants with a first ischemic stroke event, 208 had a diagnosis of AF that preceded or coincided with the diagnosis of stroke.
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Individual Genetic Variants and Risk for Incident AF
We genotyped 12 SNPs reported in the literature to be associated with AF at a genome-wide significance level (P<5×10 -8 ). None of the 12 SNPs deviated from Hardy-Weinberg equilibrium assumptions (P>0.1). We tested the association of each SNP with incident AF and for all 12 SNPs, the effect size estimates were in the same direction as those reported in the literature. For 10 of these SNPs, the association exceeded nominal significance in the MDC study (P<0.05; Table 1 ). In this study population, a model that includes these 10 SNPs provide as much information about genetic risk for AF as a model that includes all 12 SNPs according to both forward and backward model selection algorithms. The magnitude of effect conferred by individual SNPs in MDC was consistent with the original discovery reports (correlation coefficient=0.98; P=1.2×10 
Multilocus AF-GRS and Risk for Incident AF
We calculated a weighted 12-SNP AF-GRS for each participant using the literature risk estimates as weights for the minor allele of each of the 12 SNPs. The AF-GRS in the study population ranged from −1.028 to +2.198. The median AF-GRS was 0.529 (interquartile range, 0.262-0.795) among those with incident AF event and 0.431 (interquartile range, 0.206-0.684) among those who did not experience an incident AF event. The prevalence of each of the 12 SNPs and the contribution of each weighted SNP to the AF-GRS in each quintile is provided in Table II in the online-only Data Supplement.
The probability of a first AF event, assessed from the cumulative event rate after 15-year follow-up increased smoothly with increased AF-GRS ( Figure III in the online-only Data Supplement). The AF-GRS was associated with incident AF (Table 3 ; P trend =1.8×10 -28 ) after adjusting for age, sex, BMI, systolic and diastolic blood pressure, use of antihypertensive medication, smoking, diabetes mellitus, coronary events, and heart failure; and those in the top quintile of AF-GRS had a 2-fold greater risk of incident AF compared with those at the bottom quintile (hazard ratio [HR], 2.00; 95% confidence interval [CI], 1.73-2.31; P=2.7×10 -21 ). Kaplan-Meier estimates of the cumulative AF rate increased according to quintile of the AF-GRS (Figure 1 ).
Because hypertension is a clinically important modifiable risk factor for AF, we compared the AF event rate in those with a high and a low AF-GRS and in those with and without hypertension (defined as systolic blood pressure ≥140 mm Hg, Table 4 ). This rate of AF was similar to the rate among those with a high AF-GRS (Q5) but without hypertension (2.37 per 1000 person-years; 95% CI, 1.74-3.15). This equivalent magnitude of the AF-GRS and hypertension as AF risk factors was also observed among individuals above the median age. Similarly, Kaplan-Meier estimates showed that the cumulative AF rate among those with a low AF-GRS and hypertension was similar to that of participants with a high AF-GRS but without hypertension among both the old (above median age; Figure 2A ) and the young (below median age; Figure 2B ). We investigated whether the discrimination of a model based on established risk factors differed from that of a model that also included the AF-GRS. The established risk factor model was similar to those described by Schnabel et al 10 and Smith et al 34 (which included age, sex, BMI, systolic and diastolic blood pressure, use of antihypertensive medication, history of coronary events, and low-density lipoprotein cholesterol); however, the model we used replaced low-density lipoprotein cholesterol with apolipoprotein B because lowdensity lipoprotein cholesterol was not available for the entire MDC study. The c-statistic for the established risk factors model was 0.735 and increased to 0.738 (P<0.0001) after the addition of the AF-GRS to the model. To assess the discriminatory potential of AF-GRS, we also assessed continuous NRI and found that adding the AF-GRS to the established risk factors model improved reclassification (continuous NRI, 0.225; 95% CI, 0.187-0.323; P<0.0001). Among those with incident events, 54% were reclassified to higher risk and 46% to lower HRs from Cox proportional hazards models adjusted for age, sex, body mass index, systolic and diastolic blood pressure, use of antihypertensive medications, current smoking, prevalent diabetes mellitus, prevalent coronary heart disease, and prevalent heart failure. AF-GRS indicates atrial fibrillation genetic risk score; CI, confidence interval; and HR, hazard ratio. risk, whereas among those without events, 59% were reclassified to lower risk and 41% were reclassified to higher risk.
Multi-SNP AF-GRS and Risk for Incident Ischemic Stroke
The AF-GRS was associated with incident ischemic stroke (Table 3 ; P trend =0.02) after adjusting for age, sex, BMI, systolic and diastolic blood pressure, use of antihypertensive medication, smoking, diabetes mellitus, coronary events, and heart failure, an association with overall ischemic stroke that was not as strong as that of hypertension ( 
Multi-SNP AF-GRS and Risk for Likely Cardioembolic Stroke
Because a high AF-GRS could be associated with a more deleterious type of AF, we also investigated the association between the AF-GRS and ischemic stroke among patients with a diagnosis of AF (n=2139; 282 patients with prevalent and 2160 patients with incident AF, excluding 303 patients with prevalent ischemic stroke or without sufficient information). To further enrich the events for cardioembolic stroke, this end point included only ischemic stroke events that were preceded by or coincided with a diagnosis of AF (n=208). We found that the AF-GRS was associated with these likely cardioembolic stroke events after adjustment for established risk factors (age, sex, BMI, systolic and diastolic blood pressure, use of antihypertensive medication, smoking, diabetes mellitus, coronary events, and heart failure). To assess whether the AF-GRS would add to the discrimination by the CHADS 2 score among patients with AF, we compared the CHADS 2 model with a model that also included the AF-GRS for prediction of likely cardioembolic stroke. The continuous NRI indicated that adding the AF-GRS to CHADS 2 score improved reclassification (continuous NRI, 0.166; 95% CI, 0.0175-0.315; P=0.03). Among those with incident events, 51.1% were reclassified to higher risk and 48.9% to lower risk, whereas among those without events, 57.3% were reclassified to lower risk and 42.7% were reclassified to higher risk.
In contrast to the results with overall ischemic stroke, the rate of likely cardioembolic stroke among those with a low AF-GRS (first quartile) and hypertension was similar to that among those with a high AF-GRS (fourth quartile) but without hypertension: 0.19 and 0.20 per 1000 person-years for young individuals and 1.04 and 1.22 per 1000 person-years for old individuals (Table IV in the online-only Data Supplement).
Discussion
We sought to validate recently discovered genetic risk factors for AF and to estimate the magnitude of risk conferred by these genetic risk factors in 27 471 participants from a community-based prospective cohort. We found that an AF-GRS comprising 12 SNPs was associated with incident AF and ischemic stroke, even after accounting for nongenetic risk factors including age and hypertension. Individuals of European ancestry who were in the top quintile of genetic risk had an Cumulative incident atrial fibrillation events according to median age, AF genetic risk score (GRS) quintile, and hypertension status. A, Subgroup with age greater than median. Blue, The highest GRS (quintile 5) with hypertension; green, the lowest GRS (quintile 1) with hypertension; red, the highest GRS (quintile 5) without hypertension; black, the lowest GRS (quintile 1) without hypertension. Median age for this older group is 64.2 (interquartile range [IQR], 61.1-67.6) years. B, Subgroup with age below median. Blue, The highest GRS (quintile 5) with hypertension; green, the lowest GRS (quintile 1) with hypertension; red, the highest GRS (quintile 5) without hypertension; black, the lowest GRS (quintile 1) without hypertension. Median age for this group is 51.1 (IQR, 48.8-54.2) years. ≈2-fold greater risk for incident AF than those in the lowest quintile. These findings suggest several conclusions. First, the associations of SNPs with AF in the discovery genome-wide association studies seem to generalize to the community-based, prospective setting. Second, the magnitudes of effects conferred by individual SNPs in the AF-GRS are consistent with the original discovery reports. Third, when comparing risk factors for AF, having a high AF-GRS seems to confer risk equivalent to having hypertension: those with a high AF-GRS but no hypertension had a rate of future AF events similar to the rate of those with a low AF-GRS but with hypertension. And this equivalence of the AF-GRS and hypertension as AF risk factors was observed in both younger and older individuals.
Everett et al 35 reported that a similar AF-GRS was associated with incident AF in the Women's Genome Health Study (WGHS), a study that comprised a subset of the female health professionals who participated in a randomized clinical trial of aspirin and vitamin E therapy. 36 The AF-GRS in the WGHS comprised 12 SNPs, 11 of which were the same as the SNPs in the GRS of the current study and the 12th SNP in both AF-GRS studies was in the same gene (ZFHX3). In the WGHS analysis, those in the top quintile of AF-GRS had a >2-fold increased risk for incident AF in a model that adjusted for nongenetic factors. The current study extends the prediction of AF by a GRS to a community-based cohort that includes both men and women and also reports the association of an AF-GRS with ischemic stroke-a severe clinical complication of AF.
Recently, Lubitz et al 37 reported on an AF-GRS comprising 12 SNPs in the same 9 genetic loci we report here. They found that this AF-GRS was associated with AF in populations of European descent as well as in a case-control study of a Japanese population, thus providing support for the notion that an AF-GRS could be used in diverse ethnic settings. However, these investigators did not report whether adjusting for established risk factors for AF modified the magnitude of the association. And a GRS for ischemic stroke has been reported by Malik et al. 38 This GRS comprises 113 SNPs that had been previously reported to be associated with risk factors for ischemic stroke: AF, coronary artery disease, hypertension, and systolic blood pressure. This GRS was associated with ischemic stroke in a population-based validation study (P=0.016), but the association of the AF-related SNPs in the GRS with ischemic stroke or AF was not reported in that validation study.
The clinical value of using genetic markers to identify a subset of asymptomatic individuals at high risk for AF will depend on the availability of an effective intervention (diagnostic or therapeutic) that, when implemented in those at a high genetic risk, can alter health outcomes. Examples of interventions that might benefit those at high genetic risk for AF include aggressive blood pressure management and more intensive monitoring for AF in the ambulatory or postoperative settings. Further clinical studies could assess the potential benefit of additional diagnostic or therapeutic interventions among those at high genetic risk for AF.
Although risk assessment tools for cardioembolic stroke in patients with AF, such as the CHADS 2 score, are currently used to assess the potential benefit of anticoagulant therapy for stroke prevention, 39 we found that using the AF-GRS in addition to the CHADS 2 score improved risk assessment for ischemic stroke among patients with AF in this population.
Our study has several limitations. The study population is Swedish middle-aged to elderly individuals; hence, the generalizability to other ethnicities or age groups is uncertain. However, the association of an AF-GRS in a Japanese population could indicate that an AF-GRS would be useful in other populations. 37 In addition, although we could provide an estimate of the effect of the AF-GRS on risk for overall ischemic stroke, we did not have sufficient information about stroke subtypes to provide a risk estimate for validated cardioembolic stroke, a stroke subtype that is most strongly associated with AF. Also our SNP panel focused on genetic loci thought to be directly associated with AF and did not include SNPs associated with AF risk factors such as blood pressure or BMI. And information about family history of AF was not routinely available for this cohort. 40 Although incident AF have been well validated in this study, 28 the incidence rate might have been underestimated because ICD code information was derived from hospitalized participants and did not include AF diagnosis by general practitioners. Asymptomatic AF is often undiagnosed 41 and is likely underdiagnosed in this study as well. This underdiagnosis underscores the clinical need for biomarkers associated with risk of AF.
In conclusion, an AF-GRS based on 12 SNPs can identify a subset of the population at >2-fold increased risk for AF and ≈25% increased risk for ischemic stroke. Diagnostic or therapeutic interventions targeted to this subset may lower the burden of AF and stroke.
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